Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis

Summary

This phase I trial studies the side effects and best dose of daratumumab, ixazomib, and dexamethasone in treating participants with amyloid light chain amyloidosis. Monoclonal antibodies, such as daratumumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as ixazomib and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving daratumumab, ixazomib, and dexamethasone may be effective in treating participants with light chain amyloidosis.

Timeline

Start

2018-02-07

Primary completion

2026-06-17

Completion

2026-06-17

Publications

• Results Lee HC, Becnel MR, Feng L, Pasvolsky O, Murga A, Johnson RJ, Thomas SK, Bashir Q, Qazilbash MH, Steiner R, Iyer SP, Weber DM, Patel KK, Kaufman GP, Manasanch EE, Orlowski RZ. A Phase 1 Study of Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis. Am J Hematol. 2026 Jun;101(6):1187-1191. doi: 10.1002/ajh.70239. Epub 2026 Feb 19. No abstract available.

Drugs

Indications